Page 28 - Biological E News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Representative Image Biological E ties up with Canada's Providence to produce mRNA COVID-19 vaccine, to run trials in India and seek EUA ANI | Updated: Jun 01, 2021 19:18 IST Hyderabad (Telangana) [India], June 1 (ANI): Biological E. Limited has tied up with Canada's Providence Therapeutics to locally manufacture its mRNA coronavirus disease (COVID-19) vaccine, the Hyderabad-based company announced on Tuesday, adding it will run a pivotal trial in India, and seek emergency-use authorisation (EUA). According to a release issued by Biological E, the term sh...

Biological E. will run a clinical trial of Providence's vaccine in India and seek emergency use approval for it, the company said in a statement

Providence will sell up to 30 million doses of its mRNA vaccine to Biological E. (Representational) Hyderabad-based Biological E said on Tuesday it has entered into a licensing agreement with Providence Therapeutics Holdings to manufacture the Canadian company's mRNA COVID-19 vaccine in India. Biological E., which also has a separate deal to produce about 600 million doses of Johnson & Johnson's COVID-19 shot annually, will run a clinical trial of Providence's vaccine in India and seek emergency use approval for it, the company said in a statement. Providence will sell up to 30 million doses ...

The 2-billion Vaccine Question: How realistic are estimates and what's the current status? SECTIONS Share Synopsis ​The Centre’s plan for 2 billion doses of Covid-19 vaccines by year-end depends on a massive ramp-up of production as well as flawless trials, approval and manufacturing of five new vaccines. How realistic are the estimates? In what stages are the new vaccines now? AP Amid a shortage of Covid-19 vaccines, which has seen many states suspend inoculation sessions, the Centre on May 13 announced that 2 billion doses would be available by the end of the year. This would be a signi...

Biological E to produce J&J's COVID-19 vaccine alongside its own candidate The infrastructure and plants are completely separate for both the products and we will be producing both independent of each other, Biological E's managing director Mahima Datla said Reuters | May 19, 2021 | Updated 11:42 IST India's Biological E. will produce the Johnson & Johnson COVID-19 vaccine alongside its own candidate, its managing director told Reuters on Tuesday, which could boost the country's overall supplies amid a shortage. "The infrastructure and plants are completely separate for both the products and...